Rifai K, Bahr M J, Cantz T, Klempnauer J, Manns M P, Strassburg C P
Department of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Hannover, Germany.
Transplant Proc. 2005 May;37(4):1918-9. doi: 10.1016/j.transproceed.2005.02.102.
Little is known about hearing impairment in patients after organ transplantation. Few cases of hearing loss associated with different immunosuppressants have been published. To evaluate severe hearing impairment in patients after liver transplantation (OLT), all living adult patients in need of a hearing aid were analyzed. Out of 521 transplanted patients, 25 (5%) were identified with hearing aids. Nine (36%) of these patients either suffered from hearing loss prior to OLT or experienced risk factors such as ototoxic drugs. Of the remaining 16 patients who developed severe hearing loss after OLT (64%), half were men. Mean age was 42 +/- 18 years at OLT, which took place 8 +/- 4 years ago. Main transplantation indication was virus-induced cirrhosis (44%). In 14/16 (88%) patients, the hearing aid was bilateral. In 50% of patients, the hearing aid was necessary within 2 years post-OLT. Additional tinnitus was present in 9/16 patients (56%), otalgia in three patients (19%). Four patients (25%) reported a history of sudden deafness. In three of them, an association with high levels of calcineurin inhibitors was found. The proportion of patients receiving tacrolimus (50%) was relatively higher than those receiving cyclosporine (50%) compared to control patients (28% respectively 64%, P < .05). In conclusion, a high incidence of severe hearing loss was found in patients after liver transplantation. In most patients, onset of hearing loss is early and bilateral, suggesting a dose-dependent toxicity. The pathogenetic role of different immunosuppressants remains to be evaluated.
关于器官移植后患者的听力障碍,人们了解甚少。很少有与不同免疫抑制剂相关的听力损失病例被发表。为了评估肝移植(OLT)后患者的严重听力障碍,对所有需要助听器的成年活体患者进行了分析。在521例移植患者中,有25例(5%)被确定佩戴助听器。其中9例(36%)患者在OLT前就患有听力损失或经历过耳毒性药物等危险因素。在OLT后出现严重听力损失的其余16例患者中(64%),一半为男性。OLT时的平均年龄为42±18岁,OLT发生在8±4年前。主要移植指征是病毒诱导的肝硬化(44%)。在14/16例(88%)患者中,助听器是双侧佩戴的。50%的患者在OLT后2年内需要佩戴助听器。9/16例患者(56%)伴有耳鸣,3例患者(19%)伴有耳痛。4例患者(25%)有突发性耳聋病史。其中3例发现与高剂量的钙调神经磷酸酶抑制剂有关。与对照患者相比,接受他克莫司的患者比例(50%)相对高于接受环孢素的患者(50%)(分别为28%和64%,P<0.05)。总之,肝移植后患者中发现严重听力损失的发生率很高。在大多数患者中,听力损失起病早且为双侧性,提示存在剂量依赖性毒性。不同免疫抑制剂的致病作用仍有待评估。